About Us Scientific Advisory Board
Dr. Stuart Maddin, M.D., FRCPC
Stuart Maddin is Clinical Professor Emeritus at the Department of Dermatology and Skin Science of Dermatology (Active), Faculty of Medicine, University of British Columbia, where he is the Director of the Clinical Trials Unit.
Dr. Maddin has served in an advisory capacity to the Health Protection Branch (Ottawa), U.S. Pharmacopeial Convention (Rockville, MD), Essential Drugs for the World Health Organization (W.H.O. in Geneva) as well as AAD – Therapeutics / FDA Liaison Task Force. Dr. Maddin has also served as a member of the Board of Directors of the American Academy of Dermatology, Secretary and President of the Canadian Dermatology Association and also as Vice President of the American Dermatology Association. He was the first Canadian to be elected to the International Committee of Dermatology (ICD) and was later appointed as Secretary-General of the ICD (International League of Dermatologic Societies). Dr. Maddin is a founding member of the Regional Dermatology Training Centre in Moshi, Tanzania.
At present, Dr. Maddin is the Editor-in-Chief of Skin Therapy Letter, now in its 16th year of publication (indexed by the National Library of Medicine and viewable at www.SkinInformation.com). Dr. Maddin is co-founder and chairman of the SkinInformation.com network of dermatology-related websites, which provides comprehensive information to patients and physicians. He has authored over 60 articles in the field of dermatology.
Dr. Maddin is also the founder and director of the Dermatology Update Symposium which is now in its 27th year.
Dr. B. Mario Pinto, Ph.D.
Dr. Pinto is Vice President of Research at Simon Fraser University in Burnaby, BC. He leads a world class group of researchers studying the nature and origin of carbohydrate mimicry for the purpose of drug and vaccine design.
Dr. Pinto is a pioneer in the field of chemical biology having developed novel NMR/molecular modeling protocols for protein structure determination and the study of ligand topographies essential for drug and vaccine design. His work also involves the synthesis of antiviral and antibacterial drugs, bacterial vaccines, and new methods of viral control. He has authored 168 refereed scientific papers, 147 other publications which include books and technical reports, and has numerous memberships and awards, including the 1992 Horace S. Isbell Award from the Carbohydrate Division of the American Chemical Society, the 1993 Merck Frosst Award of the Canadian Society for Chemistry (CSC), the 2002 Bernard Belleau Award of the CSC, and the 2005 British Columbia Innovation Council Frontiers in Research Award. He is also a member of the Royal Society of Canada and is Chair of its Selection Committee for the Rutherford Memorial in Chemistry Medal. He has served as the President of the International Carbohydrate Organization, and serves as the Vice-President of the Canadian Society for Chemistry.
Dr. Denis Richard, Ph.D.
Dr. Denis Richard earned his Ph.D. in Physiology at Laval University and received further postdoctoral training in nutrition and physiology at the Dunn Nutrition Unit at the University of Cambridge, Cambridge, England.
Dr. Richard is a full professor at the Department of Medicine at Université Laval. Together with serving as director of the Research Centre of the Institut de Cardiologie et de Pneumologie de Québec, and director of the Groupe Interdisciplinaire de Recherche sur l’Obésité de l’Université Laval, he is the recipient of the Merck Frosst / CIHR Research Chair in Obesity, the first Chair devoted to obesity research in Canada. He is active with several societies and associations and is a member of: The Canadian Obesity Network, The American Physiological Society, The Society for Neuroscience, The Endocrine Society, and The Society for the Study of Ingestive Behavior.
Dr. Richard is a well-established scientist with regard to the study of (i) neurosystems involved in the control and regulation of food intake, thermogenesis, and energy balance, (ii) the mechanisms whereby the gastrointestinal hormones influence energy balance regulation, (iii) the relationship between stress and obesity, (iv) the role of the sympathetic nervous system in controlling uncoupling protein 1 in brown adipose tissue, and (v) the role of uncoupling protein 2 in energy metabolism, oxidative stress and neuroprotection. He lists over 200 publications in his career.
Dr. Bruce Verchere, Ph.D.
Dr. Bruce Verchere is a Professor in the Departments of Surgery and Pathology & Laboratory Medicine at the University of British Columbia (UBC). He is also head of the Diabetes Research Program at the Child & Family Research Institute, and holds the Irving K Barber Chair in Diabetes Research. Dr. Verchere’s research aims to understand the function of pancreatic islet beta cells and their relevance in both type 1 and type 2 diabetes, with a goal of developing therapeutic approaches for enhancing beta cell survival and function. He has published more than 90 manuscripts in the field of islet biology and diabetes and has been invited to present his research worldwide. Dr. Verchere was a Senior Scholar of the Michael Smith Foundation for Health Research (MSFHR) and was awarded the UBC Outstanding Young Alumnus award in 2000 and the Canadian Diabetes Association Young Scientist award in 2006. He is currently chair of the CIHR Diabetes Obesity Lipid and Lipoprotein Disorders panel, Chair of the National Research Council of the Canadian Diabetes Association, and Chair of the MSFHR Research Advisory Council. He currently sits on the editorial board of the publications Diabetes and Canadian Journal of Diabetes.
Dr. Michael Walker, Ph.D.
Dr. Michael Walker has been a director and CEO of Verona Pharma since September 2006. He is an Emeritus Professor at the Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Canada and has founded and managed various biotech companies in Canada and the UK. His research interests are wide including many aspects of general pharmacology (from basic to clinical studies), marine toxins and respiratory and cardiac pharmacology.
Dr. Walker was the founder of Rhythm Search Developments (RSD) Ltd., which company evolved into Nortran Pharmaceuticals Inc. and subsequently Cardiome Pharma Corp. (TSX:COM, NASDAQ: CRME) whose drug, RSD1235, for the acute termination of atrial fibrillation (a disorder of heart beating), is currently the subject of a New Drug Application filed with the US Food and Drug Administration.